Abstract Background The RTS, S/AS malaria candidate vaccine is being developed with the
intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) …

Scientists hail historic malaria vaccine approval - but point to challenges ahead. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

RTS, S is the most advanced candidate vaccine against human malaria. During its
remarkable journey from conception and design in the early 1980s to the multicenter Phase …

In October, 2021, WHO recommended that the RTS, S malaria vaccine, with its strong safety
profile and high impact, be provided to children from age 5 months in regions with moderate …

Background Seasonal vaccination with the RTS, S/AS01E malaria vaccine given alongside
seasonal malaria chemoprevention (SMC) substantially reduces malaria in young children …

A workshop on implementation strategies for the introduction of the RTS, S/AS01 (RTS, S)
malaria vaccine in countries with areas of highly seasonal transmission, was held as a …

Background Following a 30-year development process, RTS, S/AS01E (GSK, Belgium) is
the first malaria vaccine to reach Phase IV assessments. The World Health Organization …

An initial 18 million doses of the world's first malaria vaccine are to be rolled out across 12
African countries in the next 2 years, announced Gavi, WHO, and UNICEF, on July 5. The …

Manufactured by the Serum Institute of India, the R21/Matrix-M malaria vaccine contains the
circumsporozoite protein, secreted by the malaria parasite, fused to hepatitis B surface …

Although malaria has placed a burden on humanity for centuries, affecting millions of
people, particularly in Africa, numerous strategies and interventions have been implemented …